F Stephen Hodi
Dana-Farber Cancer Institute(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Immunotherapy and Immune Responses, Melanoma and MAPK Pathways, COVID-19 Clinical Research Studies
Most-Cited Works
- → Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19(2020)66 cited
- → Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab(2024)9 cited
- → Targeting RAF1 gene fusions with MEK inhibition in metastatic melanoma(2024)3 cited
- → 608 Predicting primary resistance and exploring mechanisms in patients with advanced melanoma treated with immune checkpoint inhibitors (ICIs)(2022)1 cited
- → Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047(2025)1 cited
- → 156 A novel polygenic risk score predicts immune checkpoint inhibitor-mediated dermatitis in a North American high-risk melanoma patient population(2025)
- → Phase II trial of vaccination with autologous, irradiated melanoma cells engineered by adenoviral mediated gene transfer to secrete granulocyte-macrophage colony stimulating factor in patients with stage III and IV melanoma(2024)